Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026)

Theravance Biopharma (TBPH) has reported Retained Earnings for 13 consecutive years, with -$62000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 100.01% year-over-year to -$62000.0; the TTM figure through Mar 2026 stood at -$62000.0 (down 100.01% YoY), while the FY2025 annual figure was $1.2 billion, up 219.76% from the prior year.
• Retained Earnings retreated to -$62000.0 in Q1 2026 per TBPH's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.3 billion in Q4 2022 and bottomed at -$1.8 billion in Q2 2022.
• Historically, Retained Earnings has averaged $64.7 million across 5 years, with a median of -$22000.0 in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings sank 22002350.0% — and 2023, when it soared 235.97%.
• Theravance Biopharma's Retained Earnings stood at $1.3 billion in 2022, then sank by 170.16% to -$909.1 million in 2023, then fell by 6.21% to -$965.5 million in 2024, then surged by 219.76% to $1.2 billion in 2025, then slumped by 100.01% to -$62000.0 in 2026.
• Business Quant data shows TBPH's Retained Earnings at -$62000.0 in Q1 2026, $1.2 billion in Q4 2025, and -$920.7 million in Q3 2025.